BOLERO-3: Adding Everolimus Improves PFS in HER2+ Breast Cancer

The addition of everolimus (Novartis) to combination trastuzumab/vinorelbine leads to a significant improvement in progression-free survival compared with placebo in advanced and metastatic HER2-positive breast cancer.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news